These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32736411)

  • 21. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    He YL; Sabo R; Riviere GJ; Sunkara G; Leon S; Ligueros-Saylan M; Rosenberg M; Dole WP; Howard D
    Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
    Pietanza MC; Litvak AM; Varghese AM; Krug LM; Fleisher M; Teitcher JB; Holodny AI; Sima CS; Woo KM; Ng KK; Won HH; Berger MF; Kris MG; Rudin CM
    Lung Cancer; 2016 Sep; 99():23-30. PubMed ID: 27565909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
    Padhi D; Sullivan JT
    Drugs R D; 2007; 8(2):79-87. PubMed ID: 17324005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW; Pradko JF; Muir KT
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation.
    Fan L; Wang JC; Jiang F; Tan ZR; Chen Y; Li Q; Zhang W; Wang G; Lei HP; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Apr; 65(4):403-9. PubMed ID: 19066872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
    Martin P; Gillen M; Ritter J; Mathews D; Brealey C; Surry D; Oliver S; Holmes V; Severin P; Elsby R
    Drugs R D; 2016 Mar; 16(1):93-107. PubMed ID: 26748647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
    Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R
    Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.
    Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.
    Farid NA; Payne CD; Ernest CS; Li YG; Winters KJ; Salazar DE; Small DS
    J Clin Pharmacol; 2008 Jan; 48(1):53-9. PubMed ID: 18094219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
    Khatri A; Cheng L; Camez A; Ignatenko S; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Jun; 58(6):805-814. PubMed ID: 30574672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
    Walker G; Mandagere A; Dufton C; Venitz J
    Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
    Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
    Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
    Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.
    Kong AN; Tomasko L; Waldman SA; Osborne B; Deutsch PJ; Goldberg MR; Bjornsson TD
    J Clin Pharmacol; 1995 Oct; 35(10):1008-15. PubMed ID: 8568008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.